Stockreport

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients wi...

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significance (p -- Obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by appr [Read more]